Upcoming SlideShare
Loading in...5

Like this? Share it with your network

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 1. Tumor Immunology
    • evidence for immune reactivity against tumor
    • changes in cellular characteristics due to malignancy
    • tumor and host components which affect tumor progression
    • use of tumor antigens in diagnosis and immunotherapy
  • 2. Evidence for immunosurveillance Infiltration of malignant tissue
  • 3. Association between immunodeficiency and cancer
    • primary (inherited) immunodeficiency
    lymphomas Burkitt’s lymphoma
    • malaria
    • secondary (acquired) immunodeficiency
    lymphoma, cervical cancer, liver cancer, skin cancer, Kaposi’s sarcoma.
    • autoimmunity
    lymphoma malignancy cause of immuno-deficiency
  • 4. Tumors stimulate an immune response
    • Animals can be immunized against tumors
    • Immunity is transferable from immune to naïve animals
    • Tumor specific antibodies and cell have been detected in humans with some malignancies
  • 5. Neo-antigens of immunologic significance on tumor cells
    • Oncofetal/differentiation antigens
      • Alpha-feto-protein (AFP)
      • Cracino embryonic antigen (CEA)
      • CALLA (common acute lymphoblastic leukemia antigen)
    • Tumor-associated transplantation antigens
      • Tumor specific transplantation antigen
      • Virus associated shared antigens
  • 6. Alpha fetoprotein: clinical use
    • AFP increases in testicular and liver cancers
      • Aids in diagnosis and staging
      • Patient management
      • Detection of tumors
  • 7. Alpha fetoprotein: clinical use
  • 8. Alpha fetoprotein: concentrations
    • Normal concentration: <20 ng/ml
    • Abnormal concentrations
      • 100-350 possible hepatoma
      • 350-500 probable hepatoma
      • 500-100 likely hepatoma
      • >1000 HEPATOMA
  • 9. Carcinoembryonic antigen: clinical use
      • Adjunct in diagnosis
      • Staging and prognosis
      • Monitoring response to therapy
      • Detection of tumor recurrence
  • 10. Carcinoembryonic antigen: clinical use
  • 11.
    • CEA as a diagnostic adjunct
      • Symptomatic patient
      • Elevated value 5-10 times the upper limit
      • Normal value <10ng/ml
    Carcinoembryonic antigen: clinical use
  • 12. Tumor associated transplantation antigens : shared Ag on virally induced tumors
  • 13. Tumor associated transplantation antigens : unique Ag on chemically induced tumors
  • 14. Immunity against tumor All components, specific and nonspecific, humoral and cellular affect tumor progression and growth
  • 15. Escape from immunosurveillance Lack of Neo-antigens
  • 16. Escape from immunosurveillance Lack of co-stimulatory molecules
  • 17. Escape from immunosurveillance Lack of class I MHC
  • 18. Escape from immunosurveillance Tumors secrete Immunosuppressive molecules
  • 19. Escape from immunosurveillance Tumors shed their neo-antigens
  • 20. Use of tumor associated antigens
    • Raise monoclonal antibodies
      • Use antibodies for diagnosis
      • Use antibodies for therapy
    • Stimulate the in vivo specific response
      • Specific active treatment
      • Specific passive treatment
      • Adjuvant therapy to augment specific immunity
  • 21. Use of tumor associated antigens monoclonal antibodies
  • 22. Monoclonal antibodies: use as a diagnostic tool
  • 23. Immunotherapy of tumors active immunotherapy passive immunotherapy non- specific BCG, Propionibacterium acne, levamisole, etc. killed tumor cells, purified or recombinant Ag specific LAK cells, cytokines non-specific antibodies alone or conjugated with other agent, activated T cells specific
  • 24. Non-specific immunotherapy activate macrophages and NK cells IFN-  , IFN-  , IFN-  , IL-2, TNF-  cytokines interferon production pyran, poly I:C synthetic molecules activate macrophages and NK cells (via cytokines) BCG, P. acnes , muramyl dipeptide bacterial products
  • 25. Cytokine immunotherapy increased expression of class-I MHC, possible anti tumor effect remission of hairy cell leukemia, weak effect on carcinomas IFN-  , -  IFN-  increased expression of class-I MHC, Tc and NK cell activation remission of ovarian carcinoma IL-2 T cell proliferation and activation, NK cell activation remission in renal cell carcinoma and melanoma TNF-  macrophage and lymphocyte activation reduction in malignant ascites
  • 26. Genetic approaches to cancer treatment
    • Transfection with genes
      • Cytokines
      • Class I MHC
      • Co-stimulatory molecules